Research and innovation in the third millennium for patient wellbeing in the field of life sciences from digital to start-ups
By Intesa Sanpaolo
The future of pharmaceutical, biotechnological and med-tech research is increasingly based on our ability to think up innovative, sensational solutions which also make use of the digital world (think of the use of virtual models to avoid pre and clinical tests on animals and human beings) as compared to the conventional development of pharmaceutical and biomedical products. The large firms recognise this.
Already, today, two-thirds of new pharmaceutical products emerge from independent research done at innovative start-ups. This is a one-off opportunity for Italy with its rich intellectual resources and biological know-how but it is limited to the number of large sector firms: helping these initiatives requires hard work, investment, working methods and discipline but is a not-to-be-missed opportunity.